Difference between revisions of "Lung cancer after neoadjuvant therapy"
Jump to navigation
Jump to search
(+so) |
|||
| Line 1: | Line 1: | ||
'''Creating Lung cancer after neoadjuvant therapy''' is assessed using a consensus protocol.<ref>{{cite journal |authors=Travis WD, Dacic S, Wistuba I, Sholl L, Adusumilli P, Bubendorf L, Bunn P, Cascone T, Chaft J, Chen G, Chou TY, Cooper W, Erasmus JJ, Ferreira CG, Goo JM, Heymach J, Hirsch FR, Horinouchi H, Kerr K, Kris M, Jain D, Kim YT, Lopez-Rios F, Lu S, Mitsudomi T, Moreira A, Motoi N, Nicholson AG, Oliveira R, Papotti M, Pastorino U, Paz-Ares L, Pelosi G, Poleri C, Provencio M, Roden AC, Scagliotti G, Swisher SG, Thunnissen E, Tsao MS, Vansteenkiste J, Weder W, Yatabe Y |title=IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy |journal=J Thorac Oncol |volume=15 |issue=5 |pages=709–740 |date=May 2020 |pmid=32004713 |pmc=8173999 |doi=10.1016/j.jtho.2020.01.005 |url=}}</ref> | '''Creating Lung cancer after neoadjuvant therapy''' is assessed using a consensus protocol.<ref>{{cite journal |authors=Travis WD, Dacic S, Wistuba I, Sholl L, Adusumilli P, Bubendorf L, Bunn P, Cascone T, Chaft J, Chen G, Chou TY, Cooper W, Erasmus JJ, Ferreira CG, Goo JM, Heymach J, Hirsch FR, Horinouchi H, Kerr K, Kris M, Jain D, Kim YT, Lopez-Rios F, Lu S, Mitsudomi T, Moreira A, Motoi N, Nicholson AG, Oliveira R, Papotti M, Pastorino U, Paz-Ares L, Pelosi G, Poleri C, Provencio M, Roden AC, Scagliotti G, Swisher SG, Thunnissen E, Tsao MS, Vansteenkiste J, Weder W, Yatabe Y |title=IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy |journal=J Thorac Oncol |volume=15 |issue=5 |pages=709–740 |date=May 2020 |pmid=32004713 |pmc=8173999 |doi=10.1016/j.jtho.2020.01.005 |url=}}</ref> | ||
==Major pathologic response== | |||
:<math>V = T/B</math> | |||
Where: | |||
:T = tumour area. | |||
:B = tumour bed area. | |||
:V = viable tumour. | |||
Major pathologic response is defined as: V <=10%. | |||
==Sign out== | ==Sign out== | ||
<pre> | <pre> | ||
| Line 11: | Line 19: | ||
</pre> | </pre> | ||
===At cut-off value for | ===At cut-off value for major pathology response=== | ||
<pre> | <pre> | ||
The estimated viable tumour was assessed in slides C10-C13 and was determined to be: 10%. The estimated viable tumour is at the cut-off (<=10%) for 'Major Pathologic Response'.[1] Additional sections of the tumour bed are negative; thus, a 'Major Pathologic Response' is favoured. | The estimated viable tumour was assessed in slides C10-C13 and was determined to be: 10%. The estimated viable tumour is at the cut-off (<=10%) for 'Major Pathologic Response'.[1] Additional sections of the tumour bed are negative; thus, a 'Major Pathologic Response' is favoured. | ||
Revision as of 19:53, 21 February 2024
Creating Lung cancer after neoadjuvant therapy is assessed using a consensus protocol.[1]
Major pathologic response
Where:
- T = tumour area.
- B = tumour bed area.
- V = viable tumour.
Major pathologic response is defined as: V <=10%.
Sign out
At cut-up the tumour bed was estimated at 5.0 cm. The residual cancer's size is estimated as 1.5 cm (based on a linear measurement of the tumour on slide D15-D16). The estimated viable tumour was assessed in slides D14-D17 and was determined to be: 30%. The estimated viable tumour exceeds the cut-off (<=10%) for "Major Pathologic Response".[1] 1. J Thorac Oncol. 2020 May;15(5):709-740. doi: 10.1016/j.jtho.2020.01.005
At cut-off value for major pathology response
The estimated viable tumour was assessed in slides C10-C13 and was determined to be: 10%. The estimated viable tumour is at the cut-off (<=10%) for 'Major Pathologic Response'.[1] Additional sections of the tumour bed are negative; thus, a 'Major Pathologic Response' is favoured. 1. J Thorac Oncol. 2020 May;15(5):709-740. doi: 10.1016/j.jtho.2020.01.005
See also
References
- ↑ Travis WD, Dacic S, Wistuba I, Sholl L, Adusumilli P, Bubendorf L, Bunn P, Cascone T, Chaft J, Chen G, Chou TY, Cooper W, Erasmus JJ, Ferreira CG, Goo JM, Heymach J, Hirsch FR, Horinouchi H, Kerr K, Kris M, Jain D, Kim YT, Lopez-Rios F, Lu S, Mitsudomi T, Moreira A, Motoi N, Nicholson AG, Oliveira R, Papotti M, Pastorino U, Paz-Ares L, Pelosi G, Poleri C, Provencio M, Roden AC, Scagliotti G, Swisher SG, Thunnissen E, Tsao MS, Vansteenkiste J, Weder W, Yatabe Y (May 2020). "IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy". J Thorac Oncol 15 (5): 709–740. doi:10.1016/j.jtho.2020.01.005. PMC 8173999. PMID 32004713. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8173999/.